Value of Serum miR-23a, miR-30d, and miR-146a Biomarkers in ST-Elevation Myocardial Infarction

Abstract

Background The aim of this study was to analyze the relative expression level of miR-30d-5p, miR-23a-3p, and miR-146a-5p, and to comprehensively assess the diagnostic and predictive possibilities of these miRNAs. Their expression changes have not yet been sufficiently investigated during acute myocardial infarction. Therefore, it is important to comprehensively assess the diagnostic and predictive possibilities of these micro-ribonucleic acids (miRNAs). Material/Methods Random patients with ST-elevated myocardial infarction (STEMI) were enrolled into the study group. The control group was comprised of patients with no inflammation or ischemic heart disease who were hospitalized for minor elective surgery. The relative expression level for each miRNA was determined by reverse transcription quantitative polymerase chain reaction (RT-qPCR)-analysis. Results There were 88 participants enrolled into the study: 62 patients were diagnosed with STEMI and there were 26 healthy controls. Expressions of miR-30d-5p, miR-146a-5p, and miR-23a-3p were respectively 1.581-fold, 4.048-fold, and 4.857-fold lower in patients with STEMI compared to the control group patients (all P values were <0.001). Downregulation of miR-23a-3p was significantly negatively correlated with risk scores of GRACE (Global Registry of Acute Coronary Events) and APACHE II (Acute Physiology and Chronic Health Evaluation II). MiR-23a-3p was a fair predictor for STEMI: area under the curve (AUC)=0.806. Cox regression analysis revealed that expression levels of analyzed miRNAs were not significantly associated with negative endpoints at 1 month after the onset of STEMI. Conclusions All investigated miRNAs were differentially expressed when comparing patients with STEMI and control group individuals. The evaluation of miR-23a-3p expression levels in serum could be useful to assess the severity of STEMI and as a potential diagnostic biomarker of this condition. In addition, miR-23a-3p may provide limited short-term prognostic value for STEMI patients.

Genetic Dissection of Hypertrophic Cardiomyopathy with Myocardial RNA-Seq

“…Among them, Serum miR-30d has been reported to be associated with acute heart failure [56] and considered as a biomarker for diffuse myocardial fibrosis in HCM patients [13]. In addition, the expression of miR-30d-5p was decreased 1.58-fold in patients with ST-elevated myocardial infarction [57]. MiR-154 has been reported to promote myocardial fibrosis through β-catenin signaling pathways [14,58].…”

Circulating exosomal microRNA expression patterns distinguish cardiac sarcoidosis from myocardial ischemia

“…We identified 47 exosomal miRNAs having increased concentrations in AMI compared to CS serum samples ( Table 3 ). Of these, 11 miRNA transcripts were validated by qRT-PCR (Figs 5 and 6 ), and 8 of these 11 have been previously linked to human AMI {miR-1 [ 23 ]; miR-133 [ 23 , 24 ]; miR-146a [ 28 , 29 ]; miR-208b [ 23 ]; miR-335 [ 30 ]; miR-423 [ 24 ]; miR-483 [ 31 ] and miR-499 [ 27 ]}. In contrast, only 5 miRNAs showed a significantly increased concentration in CS when compared to AMI serum samples ( Table 3 ), of which 3 have been linked to myocardial disease {miR-144 (validated, Fig 6 ) [ 32 , 33 ], miR-624a and miR-624b [ 34 , 35 ]}.…”

Value of Blood-Based microRNAs in the Diagnosis of Acute Myocardial Infarction: A Systematic Review and Meta-Analysis

“…Of these articles, 21 were excluded for the following reasons: review article ( n = 4), not about AMI ( n = 14), and not a diagnostic study ( n = 3). Finally, 58 studies investigating plasma, serum, or peripheral venous blood miRNAs in the diagnosis of AMI were identified as eligible for inclusion in this systematic review (Adachi et al, 2010 ; Ai et al, 2010 ; Cheng et al, 2010 ; Corsten et al, 2010 ; D'Alessandra et al, 2010 ; Wang et al, 2010 , 2011 , 2013 , 2014 , 2016 , 2019 ; Gidlöf et al, 2011 , 2013 ; Meder et al, 2011 ; Zile et al, 2011 ; Devaux et al, 2012 , 2015 ; Long et al, 2012a , b ; Li C. et al, 2013 ; Li Y. Q. et al, 2013 ; Lu et al, 2013 ; Olivieri et al, 2013 ; He et al, 2014 ; Hsu et al, 2014 ; Huang et al, 2014 ; Li L. M. et al, 2014 ; Li Z. et al, 2014 ; Peng et al, 2014 ; Xiao et al, 2014 ; Białek et al, 2015 ; Chen et al, 2015 ; Gao et al, 2015 ; Han et al, 2015 ; Ji et al, 2015 ; Li et al, 2015 ; Liu et al, 2015 , 2018 ; Yao et al, 2015 ; Zhang L. et al, 2015 ; Zhang R. et al, 2015 ; Zhao et al, 2015 ; Ke-Gang et al, 2016 ; Shalaby et al, 2016 ; Yang et al, 2016 , 2017 ; Zhang et al, 2016 , 2018 ; Zhu et al, 2016 ; Guo et al, 2017 ; Agiannitopoulos et al, 2018 ; Fawzy et al, 2018 ; Yi and An, 2018 ; Bukauskas et al, 2019 ; Li H. et al,…”

“…Seven studies performed miRNA screening to compare blood-based miRNAs between AMI patients and control groups (Adachi et al, 2010 ; D'Alessandra et al, 2010 ; Meder et al, 2011 ; Li C. et al, 2013 ; Hsu et al, 2014 ; Huang et al, 2014 ; Li et al, 2015 ). Fifty-one articles identified miRNAs based on their own previous studies or based on the literature (Ai et al, 2010 ; Cheng et al, 2010 ; Corsten et al, 2010 ; Wang et al, 2010 , 2011 , 2013 , 2014 , 2016 , 2019 ; Gidlöf et al, 2011 , 2013 ; Zile et al, 2011 ; Devaux et al, 2012 , 2015 ; Long et al, 2012a , b ; Li Y. Q. et al, 2013 ; Lu et al, 2013 ; Olivieri et al, 2013 ; He et al, 2014 ; Li L. M. et al, 2014 ; Li Z. et al, 2014 ; Peng et al, 2014 ; Xiao et al, 2014 ; Białek et al, 2015 ; Chen et al, 2015 ; Gao et al, 2015 ; Han et al, 2015 ; Ji et al, 2015 ; Liu et al, 2015 , 2018 ; Yao et al, 2015 ; Zhang L. et al, 2015 ; Zhang R. et al, 2015 ; Ke-Gang et al, 2016 ; Shalaby et al, 2016 ; Yang et al, 2016 , 2017 ; Zhang et al, 2016 , 2018 ; Zhu et al, 2016 ; Guo et al, 2017 ; Agiannitopoulos et al, 2018 ; Fawzy et al, 2018 ; Yi and An, 2018 ; Bukauskas et al, 2019 ; Li H. et al, 2019 ; Li P. et al, 2019 ; Xue et al, 2019a , b …”

“…A random effect model was used for the meta-analysis due to significant heterogeneity (all I 2 > 50%). Forty-four individual miRNAs were identified in 43 studies (Ai et al, 2010 ; Corsten et al, 2010 ; Wang et al, 2010 , 2011 , 2014 , 2016 , 2019 ; Gidlöf et al, 2011 , 2013 ; Meder et al, 2011 ; Devaux et al, 2012 , 2015 ; Long et al, 2012a , b ; Li C. et al, 2013 ; Li Y. Q. et al, 2013 ; Olivieri et al, 2013 ; He et al, 2014 ; Hsu et al, 2014 ; Li L. M. et al, 2014 ; Li Z. et al, 2014 ; Peng et al, 2014 ; Ji et al, 2015 ; Li et al, 2015 ; Liu et al, 2015 , 2018 ; Yao et al, 2015 ; Zhang L. et al, 2015 ; Zhang R. et al, 2015 ; Ke-Gang et al, 2016 ; Shalaby et al, 2016 ; Yang et al, 2016 ; Zhang et al, 2016 , 2018 ; Zhu et al, 2016 ; Guo et al, 2017 ; Agiannitopoulos et al, 2018 ; Fawzy et al, 2018 ; Bukauskas et al, 2019 ; Li H. et al, 2019 ; Li P. et al, 2019 ; Xue et al, 2019a , b ). The sensitivity, specificity, and the corresponding SROC value with 95% CIs (95% confidential intervals) of the total miRNAs in the diagnostic of AMI were 0.82 (95% CI: 0.79–0.85), 0.87 (95 %CI: 0.84–0.90), and 0.91 (95% CI: 0.88–0.93), respectively ( Supplementary Figures 2A,B , 3A ).…”